Research programme: adenosine A3 selective antagonists - Domain Therapeutics

Drug Profile

Research programme: adenosine A3 selective antagonists - Domain Therapeutics

Alternative Names: DT 0522; DT 0738; FP 0522

Latest Information Update: 15 Jan 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Faust Pharmaceuticals
  • Developer Domain Therapeutics
  • Class 3-ring heterocyclic compounds; Pyrroles; Quinoxalines; Small molecules
  • Mechanism of Action Adenosine A3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma; Cancer; Chronic obstructive pulmonary disease; Glaucoma

Most Recent Events

  • 26 Aug 2010 Pharmacodynamics data from a preclinical trial in Glaucoma presented at the 240th American Chemical Society National Meeting (2340th-ACS-2010)
  • 20 Nov 2009 Domain Therapeutics' selective adenosine A3 antagonists programme for glaucoma is available for partnering (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top